Jamjoom Pharma’s profit grows on focus on high-margin therapeutic segments

“This consistent delivery of growth in both, top and bottom line, achieved amidst a competitive pharmaceutical landscape, is a clear indicator of Jamjoom Pharma's resilience, scalability, and future-ready approach. We will continue driving our strategic initiatives forward with focus and agility to ensure sustainable, long-term returns for our stakeholders,” Hosni added.

Jamjoom Pharma recorded growing sales momentum across its key markets during Q1 2025. In Saudi Arabia, revenue grew by 24% year-on-year (YoY). Iraq saw an impressive revenue growth of 17%, while GCC region demonstrated exceptional performance with a 16% YoY increase.

North Africa and other export markets delivered 15% growth. Egypt’s revenue grew by 11% on a constant currency basis in Q1 2025.

Jamjoom’s revenue growth was driven by exceptional performance across its core therapeutic areas. Ophthalmology and Dermatology continued to lead, collectively contributing 45% of total revenue, with YoY growth of 20% and 21%, respectively.

General Medicine posted robust growth of 32%, underscoring increased demand and effective market execution. Similarly, anti-diabetic portfolio gained strong traction, growing by 48% YoY, fueled by strategic launches and rising regional prevalence of diabetes.

Additionally, Gastrointestinal (18%) and Consumer Health (17%) segments also delivered solid growth, driven by focused marketing strategies and continued optimization of product mix.

These results underscore the company’s strategic focus on high-impact therapeutic categories, enhanced by digital enablement, real-time analytics, and seamless alignment across commercial, medical, and manufacturing teams.

Hosni clarified that total production reached 40.6 million units across Jamjoom Pharma’s three manufacturing facilities, including 33.4 million units from the main facility in Jeddah, with an 89.5% capacity utilization.

The Egypt facility produced 5.5 million units, contributing 97% to local sales, while sterile facility in Jeddah produced 1.6 million units, reflecting the ramp-up phase toward full-scale operation and enabling greater flexibility and resilience in Ophthalmology production.

He further added that Jamjoom Algeria project started delivering positive financial results, contributing profit share of SAR 4 million in Q1, compared to SAR 1.8 million in the same period of 2024.

The strategic presence in Algeria positions Jamjoom Pharma as a pivotal player for future expansion into adjacent markets across North and West Africa.

The CEO highlighted that Jamjoom Pharma anticipates a CAGR of 12–15% in revenue, alongside a target EBITDA margin range of 30% to 31.5% during (2025–2027). This outlook is driven by robust operating leverage, reduced finance costs, and continued innovation.

The company’s strategic focus remains on expanding high-value therapeutic areas, strengthening regional footprint, and initiatives in business development across high value therapeutic areas with reputable global partners.

“With disciplined cost structure and growing scale, we are confident that these pillars, combined with our resilient business model and strategic foresight, will empower us to meet evolving healthcare demands and position us for sustainable, long-term growth”, Hosni affirmed.

According to Argaam data, Jamjoom Pharma’s profits rose to SAR 157 million in Q1 2024, compared to profits of SAR 103 million during the same period in 2024.